Prof. Dr. med. Stephan Brand
Gastroenterologie | Hepatologie · Dept. I
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Häuptle R, Zwyssig S, Krieger-Grübel C, Truniger S, Koller S, Metzger-Peter K, Frei N, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Bernsmeier C, Niess J, Korte W, Bürgi J, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease. Vaccines (Basel) 2024; 12
31.10.2024STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.
31.10.2024Vaccines (Basel) 2024; 12
Woelfel Simon, Junker Daniel, Bergamin Irina, Meyer-Herbon Pamela, Stillhard Roman, Graf Nicole, Leinenkugel Georg, Dütschler Joel, König Marius, Häuptle Rahel, Zwyssig Sarah, Krieger-Grübel Claudia, Truniger Samuel, Koller Seraina, Metzger-Peter Katline, Frei Nicola Fabian, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich Werner, Friedrich Matthias, Bernsmeier Christine, Niess Jan-Hendrik, Korte Wolfgang C, Bürgi Justus J, Dulovic Alex, Schneiderhan-Marra Nicole, Semela David, Brand Stephan
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. Aliment Pharmacol Ther 2024
29.10.2024XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
29.10.2024Aliment Pharmacol Ther 2024
Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Oikonomou Vasileios, Leinenkugel Georg, Koller Seraina, Metzger-Peter Katline, Wyss Jacqueline, Krupka Niklas, Frei Nicola Fabian, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
Woelfel S, Dütschler J, Junker D, König M, Leinenkugel G, Graf N, Krieger-Grübel C, Truniger S, Franke A, Koller S, Metzger-Peter K, Oberholzer M, Frei N, Geissler N, Schaub P, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Korte W, Bürgi J, Brand S. Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease. Vaccines (Basel) 2024; 12
15.07.2024Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
15.07.2024Vaccines (Basel) 2024; 12
Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Leinenkugel Georg, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Koller Seraina, Metzger-Peter Katline, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.
Wiegand N, Geyer M, Lollo G, Wuillemin W, Aepli P, Frei R, Godat S, Manz M, Seewald S, The F, Wiest R, Borovicka J, Brand S, Buyse S, Degen L, Ehmann T, Riniker F, Riva D, Semela D, Truninger K, Utzinger E, Vonlaufen A. Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology. Praxis (Bern 1994) 2023; 112:635-641.
01.12.2023Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.
01.12.2023Praxis (Bern 1994) 2023; 112:635-641
Wiegand Nico, Geyer Martin, Lollo Gianluca, Wuillemin W A, Aepli Patrick, Frei Remus, Godat Sébastien, Manz Michael, Seewald Stefan, The Frans Olivier, Wiest Reiner, Borovicka Jan, Brand Stephan, Buyse Sophie, Degen Lukas, Ehmann Tobias, Riniker Florian, Riva Daniele, Semela David, Truninger Kaspar, Utzinger Ellen, Vonlaufen Alain
[Modern endoscopy in inflammatory bowel disease].
Truniger S, Frei R, Brand S. [Modern endoscopy in inflammatory bowel disease]. Ther Umsch 2023; 80:411-416.
01.12.2023[Modern endoscopy in inflammatory bowel disease].
01.12.2023Ther Umsch 2023; 80:411-416
Truniger Samuel, Frei Remus, Brand Stephan
Identification of IL-27 as a novel regulator of major histocompatibility complex class I and class II expression, antigen presentation, and processing in intestinal epithelial cells.
Diegelmann J, Brand S. Identification of IL-27 as a novel regulator of major histocompatibility complex class I and class II expression, antigen presentation, and processing in intestinal epithelial cells. Front Immunol 2023; 14:1226809.
25.09.2023Identification of IL-27 as a novel regulator of major histocompatibility complex class I and class II expression, antigen presentation, and processing in intestinal epithelial cells.
25.09.2023Front Immunol 2023; 14:1226809
Diegelmann Julia, Brand Stephan
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
12.08.2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
12.08.2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44 Natural Killer Cells in Ulcerative Colitis.
Baumdick M, Niehrs A, Degenhardt F, Schwerk M, Hinrichs O, Jordan-Paiz A, Padoan B, Wegner L, Schloer S, Zecher B, Malsy J, Joshi V, Illig C, Schröder-Schwarz J, Möller K, Hamburg Intestinal Tissue Study Group, Martin M, Yuki Y, Ozawa M, Sauter J, Schmidt A, Perez D, Giannou A, Carrington M, Davis R, Schumacher U, Sauter G, Huber S, Puelles V, Melling N, Klein-Franke A, International Inflammatory Bowel Disease Genetics Consortium, Altfeld M, Bunders M, Brand S. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44 Natural Killer Cells in Ulcerative Colitis. Gastroenterology 2023; 165:946-962.e13.
15.07.2023HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44 Natural Killer Cells in Ulcerative Colitis.
15.07.2023Gastroenterology 2023; 165:946-962.e13
Baumdick Martin E, Niehrs Annika, Degenhardt Frauke, Schwerk Maria, Hinrichs Ole, Jordan-Paiz Ana, Padoan Benedetta, Wegner Lucy H M, Schloer Sebastian, Zecher Britta F, Malsy Jakob, Joshi Vinita R, Illig Christin, Schröder-Schwarz Jennifer, Möller Kimberly J, Hamburg Intestinal Tissue Study Group, Martin Maureen P, Yuki Yuko, Ozawa Mikki, Sauter Jürgen, Schmidt Alexander, Perez Daniel, Giannou Anastasios D, Carrington Mary, Davis Randall S, Schumacher Udo, Sauter Guido, Huber Samuel, Puelles Victor G, Melling Nathaniel, Klein-Franke Andreas, International Inflammatory Bowel Disease Genetics Consortium, Altfeld Marcus, Bunders Madeleine J, Brand Stephan
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands B, LUCENT Study Group, Brand S. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444-2455.
29.06.2023Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
29.06.2023N Engl J Med 2023; 388:2444-2455
D'Haens Geert, Dubinsky Marla, Kobayashi Taku, Irving Peter M, Howaldt Stefanie, Pokrotnieks Juris, Krueger Kathryn, Laskowski Janelle, Li Xingyuan, Lissoos Trevor, Milata Joe, Morris Nathan, Arora Vipin, Milch Catherine, Sandborn William J, Sands Bruce E, LUCENT Study Group, Brand Stephan
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Akhlaghpour M, Haritunians T, More S, Thomas L, Stamps D, Dube S, Li D, Yang S, Landers C, Mengesha E, Hamade H, Murali R, Potdar A, Wolf A, Botwin G, Khrom M, International IBD Genetics Consortium, Ananthakrishnan A, Faubion W, Jabri B, Lira S, Newberry R, Sandler R, Sartor R, Xavier R, Brant S, Cho J, Duerr R, Lazarev M, Rioux J, Schumm L, Silverberg M, Zaghiyan K, Fleshner P, Melmed G, Vasiliauskas E, Ha C, Rabizadeh S, Syal G, Bonthala N, Ziring D, Targan S, Long M, McGovern D, Michelsen K, Brand S. Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis. Gut 2023; 72:2068-2080.
20.04.2023Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
20.04.2023Gut 2023; 72:2068-2080
Akhlaghpour Marzieh, Haritunians Talin, More Shyam K, Thomas Lisa S, Stamps Dalton T, Dube Shishir, Li Dalin, Yang Shaohong, Landers Carol J, Mengesha Emebet, Hamade Hussein, Murali Ramachandran, Potdar Alka A, Wolf Andrea J, Botwin Gregory J, Khrom Michelle, International IBD Genetics Consortium, Ananthakrishnan Ashwin N, Faubion William A, Jabri Bana, Lira Sergio A, Newberry Rodney D, Sandler Robert S, Sartor R Balfour, Xavier Ramnik J, Brant Steven R, Cho Judy H, Duerr Richard H, Lazarev Mark G, Rioux John D, Schumm L Philip, Silverberg Mark S, Zaghiyan Karen, Fleshner Phillip, Melmed Gil Y, Vasiliauskas Eric A, Ha Christina, Rabizadeh Shervin, Syal Gaurav, Bonthala Nirupama N, Ziring David A, Targan Stephan R, Long Millie, McGovern Dermot P B, Michelsen Kathrin S, Brand Stephan
Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study.
Lautenschlager S, Barry M, Rogler G, Biedermann L, Schreiner P, Siebenhüner A, Swiss IBD Cohort Study Group, Brand S. Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study. BMC Gastroenterol 2023; 23:71.
12.03.2023Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study.
12.03.2023BMC Gastroenterol 2023; 23:71
Lautenschlager Severin A, Barry Mamadou Pathé, Rogler Gerhard, Biedermann Luc, Schreiner Philipp, Siebenhüner Alexander R, Swiss IBD Cohort Study Group, Brand Stephan
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther 2022; 57:103-116.
28.10.2022Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
28.10.2022Aliment Pharmacol Ther 2022; 57:103-116
Woelfel Simon, Dütschler Joel, König Marius, Graf Nicole, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Wyss Jacqueline, Krupka Niklas, Albrich Werner, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Friedrich Matthias, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.
09.02.2022Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
09.02.2022Therap Adv Gastroenterol 2022; 15:17562848221074188
Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin
Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression.
Stallhofer J, Veith L, Diegelmann J, Probst P, Brand S, Schnitzler F, Olszak T, Török H, Mayerle J, Stallmach A, Beigel F. Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression. Clin Transl Gastroenterol 2022; 13:e00450.
13.01.2022Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression.
13.01.2022Clin Transl Gastroenterol 2022; 13:e00450
Stallhofer Johannes, Veith Lisa, Diegelmann Julia, Probst Philipp, Brand Stephan, Schnitzler Fabian, Olszak Torsten, Török Helga P, Mayerle Julia, Stallmach Andreas, Beigel Florian
A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease.
Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, Mertens J, Roth R, Clottu A, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B, Swiss IBD Cohort Study Group. A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. Br J Pharmacol 2021; 178:3157-3175.
10.03.2021A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease.
10.03.2021Br J Pharmacol 2021; 178:3157-3175
Ruiz Florian, Wyss Annika, Rossel Jean-Benoit, Sulz Michael Christian, Brand Stephan, Moncsek Anja, Mertens Joachim C, Roth René, Clottu Aurélie S, Burri Emanuel, Juillerat Pascal, Biedermann Luc, Greuter Thomas, Rogler Gerhard, Pot Caroline, Misselwitz Benjamin, Swiss IBD Cohort Study Group
Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
Sawatzki M, Gueller U, Güsewell S, Husarik D, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. J Hepatol 2021; 74:419-427.
12.02.2021Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
12.02.2021J Hepatol 2021; 74:419-427
Sawatzki Mikael, Gueller Ulrich, Güsewell Sabine, Husarik Daniela B., Semela David, Brand Stephan
[Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]
Misselwitz B, Rickenbacher A, Brand S. [Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]. Ther Umsch 2021; 78:547-558.
01.01.2021[Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]
01.01.2021Ther Umsch 2021; 78:547-558
Misselwitz Benjamin, Rickenbacher Andreas, Brand Stephan
Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
Sawatzki M, Guller U, Güsewell S, Husarik D, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. Journal of hepatology 2020; online
13.10.2020Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
13.10.2020Journal of hepatology 2020; online
Sawatzki Mikael, Guller Ulrich, Güsewell Sabine, Husarik Daniela, Semela David, Brand Stephan
TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update
Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion 2020; 101 Suppl 1:16-26.
31.07.2020TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update
31.07.2020Digestion 2020; 101 Suppl 1:16-26
Vulliemoz Marianne, Brand Stephan, Juillerat Pascal, Mottet Christian, Ben-Horin Shomron, Michetti Pierre, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.
Schnitzler F, Friedrich M, Angelberger M, Diegelmann J, Stallhofer J, Wolf C, Dütschler J, Truniger S, Olszak T, Beigel F, Tillack C, Lohse P, Brand S. Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery. PloS one 2020; 15:e0236421.
27.07.2020Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.
27.07.2020PloS one 2020; 15:e0236421
Schnitzler Fabian, Friedrich Matthias, Angelberger Marianne, Diegelmann Julia, Stallhofer Johannes, Wolf Christiane, Dütschler Joel, Truniger Samuel, Olszak Torsten, Beigel Florian, Tillack Cornelia, Lohse Peter, Brand Stephan